ClinicalTrials.gg
CompletedNCT07934836Updated Nov 13, 2026

Comparing Two Hemodialysis Systems in Adults Receiving Dialysis Twice a Week in Yogyakarta, Indonesia

An interventional study of Robust RB-KRC-HMD-U01 with WOLFGANG HD18M and Nikkiso DBB-EXA ES with Purifier H180 in Hemodialysis and End Stage Chronic Renal Failure, sponsored by Bethesda Hospital Yogyakarta. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Primary conditionKidney Failure, ChronicRegistry: Renal Insufficiency, ChronicReclassifiedWhy we changed it
Registry
Renal Insufficiency, Chronic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's listed conditions name Kidney Failure, Chronic, a narrower term within Renal Insufficiency, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bethesda Hospital Yogyakarta · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Apr 2026, registered Nov 2026).
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Hemodialysis uses a machine and a filter to remove waste products such as urea from the blood. This study compared a new dialysis system with the system already in use at Bethesda Hospital in Yogyakarta, Indonesia. The main question was whether the new system could deliver a dialysis dose close to that of the established system during a single treatment.

Adults receiving dialysis twice a week were scheduled for two treatments with the new system, followed by two with the established system. The researchers measured blood urea before and after each treatment to estimate the dialysis dose. They also measured changes in other blood substances and recorded adverse events.

Read the detailed description

This prospective, single-center, nonrandomized study enrolled adults aged 18 to 75 years who had received maintenance hemodialysis for at least three months at Bethesda Hospital in Yogyakarta, Indonesia. All participants followed a twice-weekly dialysis schedule and had arteriovenous fistula access.

Each participant was scheduled for four sessions over two weeks. The first two sessions used the Robust RB-KRC-HMD-U01 machine with the WOLFGANG HD18M dialyzer. The next two used the Nikkiso DBB-EXA ES machine with the Purifier H180 dialyzer. Within each participant, prescribed treatment duration, blood flow rate, and dialysate flow rate were matched across periods. Ultrafiltration was individualized according to clinical need. Both the machine and dialyzer changed between periods, and all participants received the systems in the same order without a washout. The design therefore compared the two complete systems and could not separate their effects from treatment order or distinguish the contribution of the machine from that of the dialyzer.

The primary outcome was per-session single-pool Kt/V (spKt/V), a measure of urea-based dialysis dose calculated using the second-generation Daugirdas equation. The two session values were averaged within each participant and treatment period. The planned noninferiority comparison used the paired difference in spKt/V, calculated as new system minus established system, with a prespecified margin of -0.15.

Other assessments included the per-session urea reduction ratio, serum chemistry, blood counts, blood pressure, body weight, and achieved ultrafiltration. For the exploratory beta-2-microglobulin outcome, the intended sampling times were immediately before the first session and immediately after the second session of each period. The difference between these concentrations represented the change over two sessions. Adverse events were documented during the study, and serious adverse events were summarized according to the system each participant had received.

02

Conditions studied

  • Hemodialysis
  • End Stage Chronic Renal Failure

Browse trials for

Keywords

  • hemodialysis
  • end stage renal disease
03

In context

Kidney Failure, Chronic Reclassified

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

This study's enrollment of 20 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

This is the only study on the registry with Bethesda Hospital Yogyakarta as lead sponsor.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-75 years receiving maintenance hemodialysis for at least three months on a twice-weekly schedule, with arteriovenous fistula access, use of the unit's standard heparin regimen and written .

Exclusion criteria

Exclusion Criteria:

  • Hemodiafiltration or routine hemoperfusion, active infection or inflammatory illness, planned kidney transplant or transition to peritoneal dialysis, or active infection.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    New system followed by established system

    Device: Robust RB-KRC-HMD-U01 with WOLFGANG HD18M · Device: Nikkiso DBB-EXA ES with Purifier H180

Interventions

  • DeviceRobust RB-KRC-HMD-U01 with WOLFGANG HD18M

    Two successive hemodialysis sessions with this machine and its single-use dialyzer in period 1

  • DeviceNikkiso DBB-EXA ES with Purifier H180

    Two successive hemodialysis sessions with this machine and its single-use dialyzer in period 2

06

What researchers measure

Primary outcomes

  1. Single-pool Kt/V per dialysis session

    Unitless urea-based dose estimated by the second-generation Daugirdas equation from pre- and postdialysis urea and session data. The two session values were averaged within participant and period.

    Time frame: Before and after each of four scheduled dialysis sessions, two per period, over approximately two weeks.

Secondary outcomes

  1. Urea reduction ratio

    Percentage fall in blood urea, calculated as 100 × (predialysis urea - postdialysis urea) / predialysis urea

    Time frame: Before and after each scheduled dialysis session in each two-session period, over approximately two weeks

Other outcomes

  1. Two-session change in serum beta-2-microglobulin concentration (mg/L)

    End-of-period minus start-of-period concentration

    Time frame: Immediately before session 1 and intended immediately after session 2 in each period, over approximately two weeks.

07

Study locations

1 site
  • Bethesda Hospital, Outpatient Hemodialysis Unit
    Yogyakarta, Special Region of Yogyakarta 55224, Indonesia
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — The study team does not plan to share individual participant data. The available study records include aggregate results, but a complete, verified dataset linking each participant's measurements across the two treatment periods is unavailable for release. The study findings will be reported in aggregate.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Apr 2026, 0 months.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 0 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 13, 2026
StartActual
Apr 15, 2026
Primary completionActual
Apr 30, 2026
CompletionActual
May 16, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934836
Lead sponsor
Bethesda Hospital Yogyakarta
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Apr 15, 2026
Primary completion
Apr 30, 2026
Completion
May 16, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion